AHIP CEO: “We Are Laser-Focused on Affordability”
Rising healthcare costs are a key focus for AHIP, whose CEO says the group is pushing reforms to boost competition and reduce administrative burden.
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.
Virtual Specialty Care Has Time. Will We Use It Wisely?
The specialty access and capacity crisis demands more than incremental fixes. It requires expanding virtual access and fundamentally rethinking how specialty care can be delivered.
AI Won’t Replace Clinical Trial Teams, But It Fixes the Bottlenecks That Keep Patients Out
We don’t have a shortage of willing patients — instead we have a shortage of scalable ways to identify and engage them responsibly. AI, used meaningfully offers a reliable path forward.
Why Pure DTC Doesn’t Work in Healthcare, Per Muse Capital
Rachel Springate, general partner at Muse Capital, said the next wave of healthcare startups will be driven by consumer demand — but pure direct-to-consumer models rarely work. Companies like Midi Health, Mavida Health and Mahmee are showing a different path: starting with patients, collecting outcomes data, and integrating with clinicians, payers and the broader healthcare system.